Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
3(50.0%)
Phase 1
2(33.3%)
N/A
1(16.7%)
6Total
Phase 2(3)
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01869725Phase 2Completed

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Role: lead

NCT01619865Phase 1Completed

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

Role: lead

NCT03923257Phase 1Withdrawn

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Role: lead

NCT02441062Phase 2Completed

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

Role: lead

NCT03013387Phase 2Withdrawn

Dosimetry Guided PRRT With 90Y-DOTATOC

Role: lead

NCT02194452Not ApplicableWithdrawn

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

Role: lead

All 6 trials loaded